PRODUCT

Livagen (20 mg Vial)

No short description available.

Quickstart Highlights

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator studied for its effects on peptidase inhibition and epigenetic modulation in aging tissues[1][4]. Preclinical research demonstrates Livagen strongly inhibits enkephalin-degrading enzymes[1] and induces heterochromatin decondensation with gene reactivation in aged cells[4]. No standardized human dosing exists; this educational protocol presents a once-daily subcutaneous approach based on analogy with similar peptide bioregulators.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
Typical daily range: 0.5–2.0 mg once daily (gradual titration over 8–12 weeks).
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 0.0667 mg (66.7 mcg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light.
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Protocol Overview

Goal:Support cellular homeostasis and regenerative processes in aging tissues[3].
Schedule:Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range:0.5–2.0 mg daily with gradual titration.
Reconstitution:3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosage Protocols

Start:0.5 mg daily; increase by ~0.5 mg every 1–2 weeks as tolerated.
Target:1.5–2.0 mg daily by Weeks 5–12.
Frequency:Once per day (subcutaneous).
Cycle Length:8–12 weeks; optional extension to 16 weeks.
Timing:Any consistent time; rotate injection sites.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container[5].
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[6].
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
No standardized human clinical administration studies exist for Livagen; dosing is extrapolated from preclinical data and similar peptide bioregulators.

How It Works

Livagen’s mechanisms involve peptidase inhibition and epigenetic modulation. The peptide strongly inhibits enkephalin-degrading enzymes (IC50 ≈ 20 μM) in human serum[1], which may prolong endogenous enkephalin activity. Notably, this occurs without direct opioid receptor binding[1]. In aging cells, Livagen has been shown to induce heterochromatin decondensation and reactivate ribosomal genes[4]. Preclinical studies in rat liver organ cultures demonstrated enhanced cellular structure and regenerative processes[3], while oral administration in aged rats shifted digestive enzyme activities toward youthful patterns[2].

Lifestyle Factors

Maintain a balanced, nutrient-dense diet to support cellular health.
Engage in regular physical activity to reinforce metabolic and regenerative adaptations.
Prioritize sleep quality and stress management to support overall homeostasis.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry[6].
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][8].
Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[6].
Dispose of used syringes immediately in a sharps container[5].

Benefits and Side Effects

Benefits

Supports inhibition of enkephalin-degrading enzymes, potentially prolonging endogenous enkephalin signaling[1].
May modulate gene expression and chromatin structure in aging tissues[4].
Preclinical evidence suggests support for cellular homeostasis and regenerative capacity[3].
In aged rodents, oral dosing normalized digestive enzyme activity toward youthful levels[2].

Side Effects

Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

Livagen (20 mg Vial)

Resources

Categories

Company